We had 0 institutions before we did the uplist. So what we want to do is with results, be results-oriented and continue to do what we’re doing. And we believe the stock price will take care of itself. We don’t like it where it is to date. No doubt. Pete, do you want to amplify that?
Pete Conley: Ron, if I could add to your comments to the specific question, what is the company doing to build confidence. And I think if you go visit our website and look at the research and validation section of the website, you will see something that I don’t think any of the other companies in our sector do. We publish our clinical studies. We publish our posters. We publish our manuscripts. When you review these documents, we very clearly educate the market as to what we’re doing. And through that education, one can see that what we’re doing is quite different from anybody else. And so as Ron indicated earlier, we are committed to education. We are committed to transparency and these papers, I think, inform investors. And I think an informed investor can become a confident investor if one studies the differences, and they’re quite apparent.
Next question, how did the company utilize the Gen 1 device? Well, the Gen 1 device now was announced about 2 months ago. We are using the device actively in our testing. We are actively conducting testing with the Gen 1 in parallel with ongoing clinical research using our stationery lab system. And the parallel path is the best practice when introducing new environmental and human factors of the testing protocol. And there’s a follow-on question. How many Gen 1 devices have been constructed and sent out for use in the real world? As we sit here and speak now, about a dozen units have been built. We have a component inventory to build 100. We anticipate reaching that number somewhere towards the end of the year or early 2024. Once we get to what we would consider a characterized sensor with the appropriate algorithms, we will begin to have external testing.
We would expect the first external testers at the end of the year, beginning of 2024.
Ron Erickson: I think I want to just add something about the Gen 1 devices by the way, and you saw a video, you saw the video in June. Those are all hand-built, right? Everyone’s hand-built. We’re now doing work, as I indicated earlier, on Gen 2. Gen 2 will be designed for manufacturing. And that will be done in concert with our manufacturing partner, RaySearch technologies that we’ve spoken of in the past. So that’s a very different circumstance. When you’re designing something for manufacturing where they have the opportunity to do significant unit volume, and that’s the product Gen 2 that is likely to be the product that would then find its way ultimately the FDA trials and into the marketplace because you could build unit volume.
These are hand-built. And these are really — the Gen 1, it’s about the size of a mouse. You’ve all seen pictures of it, and you’ve seen kind of how it relates to the size of a human hand, if you will. That’s really a sort of a research lab in your pocket. That real focus is for gathering data. And so they’re robust and they’re hand-built.
